OrbiMed Advisors LLC's Form 4 filing
Corvus Pharmaceuticals, Inc. (CRVS) · filed May 8, 2024
- Accession no.
- 0000947871-24-000450
- Filed
- May 8, 2024, 8:28 PM ET
- Trade date
- May 6, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 derivative transactions. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| OrbiMed Advisors LLCCIK 0001055951 | Director, 10% Owner |
| OrbiMed Capital GP V LLCCIK 0001615374 | Director, 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
This filing has no transactions of this kind.
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 6, 2024 | Common Stock | PPurchaseAcquired | +1,444,085 | $1.73 | +$2,499,855.54 | 1,444,085 | Indirect | |
| May 6, 2024 | Common Stock | PPurchaseAcquired | +1,397,684 | –F5 | – | 1,397,684 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F5
Issued at no additional consideration to OPI V in connection with its subscription of Pre-Funded Warrants for shares of the Issuer's Common Stock at a price of $1.7311.
Referenced by the price of 1 transaction in Table II.